Equivalence of ELISpot Assays Demonstrated between Major HIV Network Laboratories

From:
Department for International Development
Published
1 January 2010
Document Type:
Journal Article
Theme:
Health
Authors:
Kaleebu, P., Birungi, J., Clark, L., Gilmour, J., Cox, J.H., Hayes, P., Tarragona-Fiol, T., Gill, D.K., Huang, Y., Kopycinski, J., Carter, D.K., Hahn, B., Hong Wan, Hural, J., Juliana McElrath, M., Koup, R., Levine, G.L., Randles, M., Raxworthy Cooper, A., Sambor, A., Sato, A., Self, S.G., Ssemaganda, A., Wood, B.

Abstract

The Comprehensive T Cell Vaccine Immune Monitoring Consortium (CTC-VIMC) was created to provide standardized immunogenicity monitoring services for HIV vaccine trials. The ex vivo interferon-gamma (IFN-γ) ELISpot is used extensively as a primary immunogenicity assay to assess T cell-based vaccine candidates in trials for infectious diseases and cancer. Two independent, GCLP-accredited central laboratories of CTC-VIMC routinely use their own standard operating procedures (SOPs) for ELISpot within two major networks of HIV vaccine trials. Studies are imperatively needed to assess the comparability of ELISpot measurements across laboratories to benefit optimal advancement of vaccine candidates.

The described study procedure provides a prototypical example for the comparison of bioanalytical methods in HIV vaccine and other disease fields. This study also provides valuable and unprecedented information for future vaccine candidate evaluations on the comparison and pooling of ELISpot results generated by the CTC-VIMC central core laboratories.

Citation

PLoS ONE (2010) 5 (12): e14330. [doi:10.1371/journal.pone.0014330]

Equivalence of ELISpot Assays Demonstrated between Major HIV Network Laboratories

Updates to this page

Published 1 January 2010
Contents